Evidence map›Paper›PMID 19680460›Full record

ReviewJournal of innate immunity2009

Antiviral activity of innate immune protein ISG15.

Ronald N Harty, Paula M Pitha, Atsushi Okumura

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of innate immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 100 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evasion of the Host Immune Response by Betaherpesviruses.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Viruses go modular.The Journal of biological chemistry · 2020
    Review
  10. Article
  11. Structural Variability in the RLR-MAVS Pathway and Sensitive Detection of Viral RNAs.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2019
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Cell type-dependent regulation of free ISG15 levels and ISGylation.Journal of cell communication and signaling · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ronald N HartyDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. rharty@vet.upenn.edu
Paula M Pitha
Atsushi Okumura
University of Pennsylvania · USJohns Hopkins University · US

Funding

VIRUS/IFN INDUCED SIGNALING PATHWAY IN PATHOGENICITYR01AI019737 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PITHA-ROWE, PAULA M · 1985 to 2006
$1.6M
Role of ISG15 in Inhibition of Ebola Virus BuddingR21AI077014 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HARTY, RONALD N · 2007 to 2009
$615k
Role of Transcription Factor IRF-5 in Infected CellsR21AI019737 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PITHA-ROWE, PAULA M · 2001 to 2001
$286k
NIAID NIH HHS AI-077014-02NIAID NIH HHS AI-19737-23NIAID NIH HHS R01 AI019737NIAID NIH HHS R21 AI019737NIAID NIH HHS R21 AI077014
6 · The paper itself

Abstract

The host innate immune response, including the production of type-I IFN, represents the primary line of defense against invading viral pathogens. Of the hundreds of IFN-stimulated genes (ISGs) discovered to date, ISG15 was one of the first identified and shown to encode a ubiquitin-like protein that functions, in part, as a modifier of protein function. Evidence implicating ISG15 as an innate immune protein with broad-spectrum antiviral activity continues to accumulate rapidly. This review will summarize recent findings on the innate antiviral activity of ISG15, with a focus on the interplay between ubiquitination and ISGylation pathways resulting in modulation of RNA virus assembly/budding. Indeed, ubiquitination is known to be proviral for some RNA viruses, whereas the parallel ISGylation pathway is known to be antiviral. A better understanding of the antiviral activities of ISG15 will enhance our fundamental knowledge of host innate responses to viral pathogens and may provide insight useful for the development of novel therapeutic approaches designed to enhance the immune response against such pathogens.

Indexed as

Immunity, InnateAnimalsAntiviral AgentsCytokinesDNA VirusesMiceRNA VirusesUbiquitinsVirus DiseasesAntiviral AgentsCytokinesISG15 protein, humanUbiquitinsAntiviralBuddingInnate immunityInterferon-stimulated gene 15ISGylationUbiquitinUbiquitination

Identifiers

PMID19680460
PMCPMC2725329
OpenAlexW2092647031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.